In addition, FIDAS-5 reduces the proliferation and survival of multiple myeloma (MM) cells in vivo and in vitro by inhibiting mTOR-mediated protein synthesis and can enhance the efficacy of bortezomib, a commonly used chemotherapy drug, in MM therapy [172]. This evidence concerns the gene MTOR and Miyoshi myopathy.